Softwr

Healthcare · head to head

Oracle Clinical One vs PathAI

Oracle Clinical One logo

Oracle Clinical One

Healthcare

Unified clinical trial data collection and randomisation on one Oracle Life Sciences platform

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Oracle Clinical One nothing about the commercial terms is published, so cost, implementation length and validation scope all emerge inside an enterprise sales process, and comparison shopping requires running parallel procurements.; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Oracle Clinical One covers Unified platform, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Oracle Clinical One and PathAI actually diverge.

Attributes where Oracle Clinical One and PathAI differ
AttributeOracle Clinical OnePathAI
PlatformsWeb, iOS, AndroidWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Oracle Clinical One

  • Unified platform
  • Data collection
  • Randomisation and supplies
  • No-code study build
  • Regulatory compliance
  • Mid-study changes
  • Integrations
  • Cloud delivery

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Oracle Clinical One

  • A sponsor running a complex Phase III where randomisation errors between separate EDC and RTSM vendors have already cost timenot PathAI
  • A pharmaceutical company already on Oracle Clinical or InForm that needs a supported migration path off end-of-life systemsnot PathAI
  • A trial with adaptive randomisation and drug supply forecasting that would otherwise need custom programming per amendmentnot PathAI
  • A CRO standardising study build across many sponsor programmes on one validated platformnot PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Oracle Clinical One
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Oracle Clinical One
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Oracle Clinical One
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Oracle Clinical One

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Oracle Clinical One

  • Nothing about the commercial terms is published, so cost, implementation length and validation scope all emerge inside an enterprise sales process, and comparison shopping requires running parallel procurements.
  • Placing data collection and randomisation with a single vendor concentrates risk: an outage or a defect affects both of the systems your sites cannot work without.
  • Mid-study amendments are routine in trials but flow through the vendor change control process, and change orders are where the real cost of an Oracle trial platform accumulates after signature.
  • Implementation and study build require specialist staff or Oracle services, so the practical time from contract to first patient in is measured in months, not weeks.
  • It is aimed squarely at sponsors and CROs with established trial operations, and a small biotech running its first study will find the platform, the contracting and the validation burden heavier than its team can absorb.

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Oracle Clinical One

On request
  • Clinical One Data Collection$undefined/year
    • Pricing only through Oracle sales
    • Priced against study count, sites and subjects
    • Study build and configuration services quoted separately
  • Clinical One Randomization and Supplies Management$undefined/year
    • Quoted alongside or independently of Data Collection
    • Randomisation strategy configuration included in the service
    • Supply forecasting and kit management

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Oracle Clinical One if

  • You need unified platform.
  • You work on Web, iOS, Android.
  • You also want data collection.
Oracle Clinical One review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Oracle Clinical One or PathAI better?
Neither clearly leads. Oracle Clinical One starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Oracle Clinical One or PathAI?
Oracle Clinical One starts at On request and PathAI at On request.
Does Oracle Clinical One or PathAI run on more platforms?
Oracle Clinical One runs on Web, iOS, Android. PathAI runs on Web.
What is Oracle Clinical One best used for?
Oracle Clinical One is most often used for a sponsor running a complex phase iii where randomisation errors between separate edc and rtsm vendors have already cost time, a pharmaceutical company already on oracle clinical or inform that needs a supported migration path off end-of-life systems, a trial with adaptive randomisation and drug supply forecasting that would otherwise need custom programming per amendment, a cro standardising study build across many sponsor programmes on one validated platform. Of those, a sponsor running a complex phase iii where randomisation errors between separate edc and rtsm vendors have already cost time and a pharmaceutical company already on oracle clinical or inform that needs a supported migration path off end-of-life systems are not what PathAI is typically brought in for.
What can Oracle Clinical One do that PathAI cannot?
Oracle Clinical One covers Unified platform, Data collection, Randomisation and supplies, No-code study build. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Oracle Clinical One: What replaced Oracle Clinical and InForm?

Clinical One is the current Oracle Life Sciences platform, and sponsors on the older Oracle Clinical and InForm products are the primary migration audience.

PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Oracle Clinical One: Can I buy randomisation without data collection?

Yes. Clinical One Randomization and Supplies Management can integrate with a third-party EDC if you want to keep an incumbent capture system.

PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Oracle Clinical One: Is pricing published?

No. Every element, including licence, study build, implementation and validation, comes through Oracle sales.

PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

Oracle Clinical One: Is it validated for regulated trials?

It is delivered as a validated cloud service with GxP documentation and Part 11 aligned audit trails, but sponsor-level validation of your own configuration remains your responsibility.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Oracle Clinical One

More on PathAI

Keep looking

Other head to heads